Navigation Links
Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference
Date:11/4/2008

SAN FRANCISCO, Nov. 4 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, today announced that David H. Kirn, M.D., President and Chief Executive Officer, will present an overview of the Company at the 10th Annual Rodman & Renshaw Healthcare Conference in New York on November 11, 2008 at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the Palace Hotel, New York.

A webcast of the presentation will be available during the event at http://www.jennerex.com and will be archived and available on the website for 3 months.

About Jennerex

Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Jennerex Clinical Trial Data with JX-594 Selected for Plenary Session Presentation at Major International Conference
2. Hospira to Present at the 2008 Annual Credit Suisse Health Care Conference on November 12
3. Alexion to Present at Investor Conferences
4. IPC The Hospitalist Company, Inc. to Present at the 2008 Annual Credit Suisse Health Care Conference
5. Jazz Pharmaceuticals to Present at Investor Conferences
6. Senesco Technologies to Present at 10th Annual Rodman & Renshaw Healthcare Conference
7. XOMA to Present at the Rodman and Renshaw Annual Global Investment Conference on November 11
8. The Quantum Group Inc. To Present at Paulson Investments 31st Annual Westergaard Conference
9. Haemacure to Present at the Rodman & Renshaw Annual Global Investor Conference
10. Response Biomedical to Present at Rodman and Renshaw 10th Annual Healthcare Conference
11. BD to Present at Investor Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... Orlando-based Maximized Living has selected Dr. Nick ... in Rio. Under the care of Maximized Living doctors at the London Olympics ... showing, Maximized Living is sending the largest contingent of elite chiropractors to Rio to ...
(Date:4/29/2016)... ... 29, 2016 , ... Memorial Healthcare System Graduate Medical ... (ACGME) that it has received accreditation for its residency program on Physical Medicine ... that Memorial is currently pursuing, including Pediatrics and Internal Medicine. This accreditation allows ...
(Date:4/29/2016)... ... April 29, 2016 , ... Dr. Bernie ... best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related to Death live ... thereafter . Dr. Bernie Siegel, author of a plethora of essential books-to-read ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a ... proud to announce one of their physicians has been invited to be a featured ... ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. Scott ...
(Date:4/29/2016)... ... ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of skin ... More than 10,000 people are expected to die of melanoma this year. The risk increases ... of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic studies ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Dr. ... und Stephen Schmidt werden Teil ... ein führender Anbieter cloudbasierter Softwarelösungen für den ... neue Führungskräfte zum Team Sicherheit und Pharmakovigilanz ... Erfahrungen mitbringen.  Dies wird die Geschäftseinheit Sicherheit ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
(Date:4/28/2016)... , April 28, 2016   Acsis , ... announced that leading IT market research and advisory firm ... in the IDC MarketScape: Worldwide Pharmaceutical Track and Trace ... The report provides an assessment of the capabilities and ... and trace software market. Logo - ...
Breaking Medicine Technology: